These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 1846551)

  • 1. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.
    Nicholson S; Richard J; Sainsbury C; Halcrow P; Kelly P; Angus B; Wright C; Henry J; Farndon JR; Harris AL
    Br J Cancer; 1991 Jan; 63(1):146-50. PubMed ID: 1846551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor and other oncogenes as prognostic markers.
    Harris AL; Nicholson S; Sainsbury R; Wright C; Farndon J
    J Natl Cancer Inst Monogr; 1992; (11):181-7. PubMed ID: 1627426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure.
    Nicholson S; Wright C; Sainsbury JR; Halcrow P; Kelly P; Angus B; Farndon JR; Harris AL
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):811-4. PubMed ID: 2285594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.
    Harris AL; Nicholson S; Sainsbury JR; Farndon J; Wright C
    J Steroid Biochem; 1989; 34(1-6):123-31. PubMed ID: 2576295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients.
    Fox SB; Smith K; Hollyer J; Greenall M; Hastrich D; Harris AL
    Breast Cancer Res Treat; 1994 Jan; 29(1):41-9. PubMed ID: 8018963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.
    Torregrosa D; Bolufer P; Lluch A; López JA; Barragán E; Ruiz A; Guillem V; Munárriz B; García Conde J
    Clin Chim Acta; 1997 Jun; 262(1-2):99-119. PubMed ID: 9204213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.
    Sainsbury JR; Farndon JR; Needham GK; Malcolm AJ; Harris AL
    Lancet; 1987 Jun; 1(8547):1398-402. PubMed ID: 2884496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer.
    Toi M; Osaki A; Yamada H; Toge T
    Eur J Cancer; 1991; 27(8):977-80. PubMed ID: 1832907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up.
    Ferrero JM; Ramaioli A; Largillier R; Formento JL; Francoual M; Ettore F; Namer M; Milano G
    Ann Oncol; 2001 Jun; 12(6):841-6. PubMed ID: 11484962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.
    Nicholson S; Halcrow P; Sainsbury JR; Angus B; Chambers P; Farndon JR; Harris AL
    Br J Cancer; 1988 Dec; 58(6):810-4. PubMed ID: 3224082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of prognostic factors in operable breast cancer.
    Hawkins RA; Tesdale AL; Killen ME; Jack WJ; Chetty U; Dixon JM; Hulme MJ; Prescott RJ; McIntyre MA; Miller WR
    Br J Cancer; 1996 Nov; 74(9):1469-78. PubMed ID: 8912547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer.
    Gasparini G; Bevilacqua P; Pozza F; Meli S; Boracchi P; Marubini E; Sainsbury JR
    Br J Cancer; 1992 Nov; 66(5):970-6. PubMed ID: 1419645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of transforming growth factors in human breast cancer.
    Murray PA; Barrett-Lee P; Travers M; Luqmani Y; Powles T; Coombes RC
    Br J Cancer; 1993 Jun; 67(6):1408-12. PubMed ID: 8390290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer.
    Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
    Breast Cancer Res Treat; 2002 Jan; 71(1):67-75. PubMed ID: 11859875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of epidermal growth factor receptor in node-positive breast cancer.
    Grimaux M; Romain S; Remvikos Y; Martin PM; Magdelénat H
    Breast Cancer Res Treat; 1989 Oct; 14(1):77-90. PubMed ID: 2690971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
    Kommoss F; Colley M; Hart CE; Franklin WA
    Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and prognostic value of EGFR in invasive breast cancer.
    Quintela I; Corte MD; Allende MT; Vazquez J; Rodríguez JC; Bongera M; Lamelas M; Gonzalez LO; Vega A; García-Muñiz JL; Astudillo A; Vizoso F
    Oncol Rep; 2005 Dec; 14(6):1655-63. PubMed ID: 16273272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.
    Nicholson S; Sainsbury JR; Halcrow P; Chambers P; Farndon JR; Harris AL
    Lancet; 1989 Jan; 1(8631):182-5. PubMed ID: 2463445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.